Bvf Partners L. P/Il Sells 50,000 Shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Stock

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) major shareholder Bvf Partners L. P/Il sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $4.50, for a total value of $225,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

PIRS stock traded up $0.54 during mid-day trading on Tuesday, hitting $5.32. The company had a trading volume of 600,036 shares, compared to its average volume of 439,723. The firm has a market cap of $232.13 million, a PE ratio of -10.64 and a beta of 1.32. Pieris Pharmaceuticals Inc has a 12 month low of $2.39 and a 12 month high of $6.04. The stock’s fifty day moving average price is $4.89 and its two-hundred day moving average price is $4.01.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PIRS. Susquehanna International Group LLP bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at approximately $209,000. Nuveen Asset Management LLC purchased a new stake in shares of Pieris Pharmaceuticals during the 2nd quarter worth approximately $3,011,000. Jane Street Group LLC purchased a new stake in shares of Pieris Pharmaceuticals during the 2nd quarter worth approximately $47,000. Citadel Advisors LLC raised its holdings in shares of Pieris Pharmaceuticals by 16.1% in the 2nd quarter. Citadel Advisors LLC now owns 159,590 shares of the biotechnology company’s stock worth $750,000 after purchasing an additional 22,124 shares during the period. Finally, D. E. Shaw & Co. Inc. raised its holdings in shares of Pieris Pharmaceuticals by 18.0% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 86,562 shares of the biotechnology company’s stock worth $407,000 after purchasing an additional 13,190 shares during the period. Hedge funds and other institutional investors own 55.11% of the company’s stock.

PIRS has been the subject of a number of research analyst reports. Robert W. Baird downgraded Pieris Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target for the company. in a research report on Tuesday, July 30th. Zacks Investment Research upgraded Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 17th. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Pieris Pharmaceuticals in a report on Thursday, August 1st. William Blair reissued a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Friday, August 16th. Finally, Cowen reaffirmed a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Monday, May 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $5.67.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

See Also: What are gap-down stocks?

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.